Genetic testing firm closes drug discovery divis
Author: Michael
Researchers develop new method to create complex
Partnership aims to bring C2N’s portfolio of A
Preclinical study investigates neuron-targeted p
Unified company aims to ‘industrialize drug di
Bioniq founder on why taking a personalized appr
Companies seek to leverage disease risk detectio
Longevity world mourns a pioneer of aging resear
Company targets Phase 2 trial of oral Alzheimer’s drug that inhibits the activity of microglia to combat neuroinflammation. US biotech NeuroTherapia has secured $12.3 million in the first close of a Series B financing round to progress its mission to tackle central nervous system diseases, with an initial focus on Alzheimer’s. While many companies are targeting the removal of toxic proteins like beta amyloid, tau and alpha synuclein, the Cleveland Clinic spinout is addressing neuroinflammation, a factor increasingly recognized as crucial in the progression of CNS diseases. NeuroTherapia’s focus is on developing orally available small-molecule drugs that inhibit the activity…
New study shows that raising levels of fatty aci